recent
discoveri
nipah
viru
niv
fusion
protein
f
activ
endosom
cathepsin
l
rais
question
niv
util
phand
proteasedepend
mechan
entri
show
niv
receptor
ephrin
viruslik
particl
infecti
niv
intern
cell
surfac
howev
endocytosi
acid
ph
cathepsinmedi
cleavag
necessari
initi
infect
new
host
cell
data
clearli
demonstr
proteolyt
activ
niv
f
protein
requir
incorpor
bud
virion
viru
entri
highli
pathogen
nipah
viru
niv
isol
outbreak
fatal
enceph
among
pig
farmer
malaysia
singapor
chua
old
world
fruit
bat
genu
pteropu
identifi
natur
host
niv
yob
et
al
sever
uniqu
genet
biolog
characterist
niv
close
relat
hendra
viru
form
new
genu
henipaviru
within
paramyxovirida
famili
harcourt
et
al
wang
et
al
due
broad
host
rang
high
mortal
rate
associ
infect
henipavirus
classifi
biosafeti
level
agent
paramyxovirus
niv
encod
two
surfac
glycoprotein
essenti
requir
viru
entri
process
bind
g
protein
cellular
surfac
receptor
fusion
protein
f
mediat
fusion
viral
cellular
membran
recent
ephrin
shown
function
main
entri
receptor
niv
bonapart
et
al
negret
et
al
transmembraneanchor
ligand
receptor
tyrosin
kinas
play
critic
role
embryon
pattern
axon
guidanc
angiogenesi
adam
kulland
klein
predominantli
express
endotheli
cell
neuron
adam
consist
known
cellular
tropism
niv
wong
et
al
success
viru
entri
cell
fusionact
niv
f
protein
requir
paramyxovir
f
protein
niv
f
protein
synthes
inact
precursor
cleav
host
cell
proteas
subunit
f
f
therebi
hydrophob
fusion
peptid
nterminu
f
releas
interestingli
recent
uncov
proteolyt
cleavag
mechan
use
henipaviru
f
protein
differ
fundament
util
relat
virus
paramyxovir
fusion
protein
either
process
extracellular
trypsinlik
proteas
reach
cell
surfac
incorpor
bud
virus
cleav
golgi
proteas
furin
transport
along
secretori
pathway
klenk
garten
f
protein
viru
particl
cleav
fulli
fusion
compet
paramyxovirus
enter
new
host
cell
via
fusion
viral
membran
plasma
membran
neutral
ph
earp
et
al
howev
henipaviru
f
protein
neither
cleav
trypsinnor
furinlik
proteas
must
activ
cathepsin
l
ctsl
within
acid
endosom
compart
meulendyk
et
al
pager
dutch
pager
et
al
cleavag
effici
strongli
depend
endocyt
activ
express
level
ctsl
vari
markedli
differ
cell
type
even
though
cleav
f
protein
express
surfac
cell
test
far
avail
onlin
wwwsciencedirectcom
virolog
wwwelseviercomlocateyviro
percentag
cleav
niv
f
protein
gener
low
moll
et
al
diederich
unpublish
thu
f
protein
present
plasma
membran
fusion
compet
rais
question
niv
particl
releas
infect
cell
contain
suffici
amount
activ
f
protein
enter
new
host
cell
directli
phindepend
fusion
plasma
membran
viru
endocytosi
subsequ
f
cleavag
endosom
ctsl
essenti
entri
process
aim
studi
clearli
defin
step
niv
replic
cycl
requir
endocyt
proteolyt
process
niv
receptor
endocytos
differ
cell
type
idea
niv
entri
via
receptormedi
endocytosi
support
recent
report
niv
receptor
intern
human
endotheli
cell
korff
et
al
analyz
endocytosi
gener
phenomenon
nivsuscept
cell
perform
qualit
uptak
assay
use
vero
mdck
paec
hela
cell
transfect
express
plasmid
addit
recombin
mous
solubl
receptor
fuse
fc
region
human
igg
cell
incub
h
allow
bind
coendocytosi
surfaceremain
stain
rhodamineconjug
secondari
antibodi
permeabil
intern
visual
incub
fitcconjug
secondari
antibodi
fig
clearli
show
numer
fluoresc
intracellular
vesicl
green
found
cell
indic
receptor
effici
endocytos
nivsuscept
cell
gcontain
vlp
niv
particl
intern
surfac
cell
determin
niv
particl
bound
cell
also
intern
made
use
recent
find
niv
g
protein
releas
viruslik
particl
vlp
upon
singl
express
patch
et
al
gcontain
vlp
resembl
infecti
niv
particl
shape
size
shown
therefor
util
studi
gmediat
attach
uptak
host
cell
outsid
facil
vlp
gener
transfect
cell
niv
g
tag
gene
h
post
transfect
supernat
clarifi
lowspe
centrifug
pellet
sucros
cushion
vlpcontain
pellet
resuspend
ad
cell
combin
antibodi
direct
hatag
h
either
surfacebound
antibodi
stain
fitcconjug
secondari
antibodi
permeabil
intern
vlp
visual
rhodamineconjug
secondari
antibodi
cell
nuclei
counterstain
dapi
merg
pictur
fitc
rhodamin
dapi
fluoresc
channel
shown
fig
expect
intracellular
vlp
could
detect
sampl
incub
fig
contrast
substanti
amount
vlp
found
within
cell
red
dot
endocytosi
allow
fig
perform
vlp
uptak
assay
presenc
sucros
known
inhibit
endocyt
uptak
gener
intern
clearli
inhibit
fig
sucros
mani
vlp
bound
surfac
sucrosetr
cell
green
dot
intracellular
vlp
found
less
frequent
order
reveal
endocyt
pathway
requir
vlp
uptak
either
chlorpromazin
inhibitor
clathrindepend
intern
mm
mcd
inhibitor
caveolaedepend
endocytosi
ad
prior
uptak
vlp
chlorpromazin
basic
neg
effect
intern
indic
clathrinmedi
endocytosi
involv
fig
chlorpromazin
contrast
mcd
remov
membran
cholesterol
disrupt
lipid
raft
therebi
prevent
uptak
via
caveola
markedli
inhibit
vlp
endocytosi
fig
mcd
quantifi
effect
inhibitor
vlp
uptak
number
intern
vlp
randomli
chosen
cell
sampl
count
averag
vlp
uptak
untreat
cell
incub
fig
set
chlorpromazin
inhibit
incub
h
allow
bind
endocytosi
proceed
surfaceremain
stain
rhodamineconjug
antihuman
igg
antibodi
surfac
fixat
permeabil
intern
detect
fitcconjug
secondari
antibodi
intracellular
endocytosi
wherea
sucros
mcd
treatment
produc
uptak
inhibit
respect
result
suggest
intern
vlp
enter
cell
via
caveosom
agreement
intern
also
significantli
reduc
presenc
sucros
mcd
data
shown
support
idea
endocyt
particl
uptak
perform
uptak
assay
use
infecti
niv
niv
particl
concentr
partial
purifi
infect
cell
supernat
virus
adsorb
vero
cell
label
antiniv
serum
subsequ
cell
either
shift
allow
endocytosi
surfacebound
virion
kept
antibodi
cell
surfac
detect
fitcconjug
secondari
antibodi
intern
virusantibodi
complex
stain
rhodaminecoupl
secondari
antibodi
cell
permeabil
cell
shift
intracellular
stain
observ
fig
numer
intracellular
red
virus
could
detect
incub
uptak
viru
particl
allow
fig
demonstr
substanti
portion
surfacebound
niv
particl
enter
cell
via
endocytosi
togeth
find
support
concept
niv
uptak
receptormedi
endocytosi
might
addit
altern
rout
viru
entri
fusion
plasma
membran
order
investig
efficaci
variou
drug
inhibitor
interfer
niv
f
cleavag
vero
cell
substanc
fig
vlpand
virusuptak
assay
vero
cell
incub
h
purifi
niv
g
tag
contain
vlp
combin
monoclon
antibodi
direct
hatag
surfacebound
vlp
visual
incub
fitcconjug
antimous
igg
antibodi
permeabil
methanolaceton
intracellular
vlp
stain
rhodamineconjug
secondari
antibodi
nuclei
visual
dapi
stain
merg
pictur
dapi
fitc
rhodamin
fluoresc
channel
shown
b
cell
preincub
min
follow
endocytosi
inhibitor
sucros
sucros
chlorpromazin
chlorpromazin
mm
mcd
incub
vlp
hatag
antibodi
perform
h
presenc
absenc
inhibitor
surfacebound
intracellular
vlp
stain
describ
c
vero
cell
incub
infecti
niv
particl
h
incub
antiniv
serum
min
ice
cell
either
shift
kept
min
surfacebound
intracellular
antibodi
visual
describ
fig
effect
endocytosi
inhibitor
nh
cl
cathepsin
inhibitor
f
protein
cleavag
vero
cell
express
niv
f
protein
radiolabel
promix
min
incub
chase
medium
contain
indic
inhibitor
h
f
protein
immunoprecipit
cell
lysat
separ
sd
gel
reduc
condit
subject
autoradiographi
either
affect
endocytosi
sucros
chlorpromazin
mcd
prevent
acidif
endosom
nh
cl
inhibit
ctslmediat
cleavag
catliii
assay
inhibitori
effect
f
protein
cleavag
ftransfect
vero
cell
metabol
label
cystein
methionin
min
incub
h
absenc
presenc
differ
concentr
variou
inhibitor
cell
lysi
f
protein
immunoprecipit
separ
sd
gel
reduc
condit
subject
autoradiographi
fig
result
shown
optim
inhibitor
concentr
thu
highest
drug
concentr
show
cytotox
effect
within
h
nonspecif
inhibit
endocyt
process
sucros
well
specif
inhibit
clathrinmedi
endocytosi
chlorpromazin
almost
complet
prevent
proteolyt
process
f
f
f
confirm
previou
find
mdck
cell
f
cleavag
depend
tyrosinedepend
motif
cytoplasm
tail
mediat
endocytosi
via
clathrinco
pit
contrast
chlorpromazin
treatment
addit
mcd
slightli
affect
f
protein
process
fig
mm
mcd
demonstr
caveolaemedi
endocytosi
predominantli
involv
fig
effect
inhibitor
treatment
viru
entri
niv
infect
inhibitor
treatment
viru
entri
vero
cell
infect
niv
moi
cell
treat
indic
inhibitor
h
prior
infect
h
viru
adsorpt
entri
left
untreat
control
inhibitor
input
viru
remov
cell
wash
incub
medium
h
fixat
permeabil
cell
incub
h
ice
polyclon
antiniv
serum
primari
antibodi
detect
rhodamineconjug
secondari
antibodi
b
inhibitor
treatment
viru
entri
infect
vero
cell
niv
h
cell
wash
incub
absenc
control
presenc
indic
inhibitor
h
pi
immunostain
perform
describ
gener
toxic
effect
inhibitor
concentr
use
experi
proteolyt
activ
newli
synthes
f
protein
even
endocyt
pathway
found
involv
vlp
uptak
might
therefor
play
role
receptormedi
niv
uptak
f
protein
cleavag
analyz
presenc
mm
nh
cl
gener
cystein
proteas
inhibitor
inhibitor
cathepsin
b
l
montas
et
al
pager
dutch
catliii
ctslspecif
inhibitor
cleavag
found
complet
prevent
fig
confirm
f
activ
vero
cell
depend
low
ph
ctsl
drug
inhibit
endocytosi
acidif
endosom
cathepsinmedi
cleavag
affect
niv
entri
later
replic
step
final
test
endocyt
uptak
andor
phdepend
cathepsinmedi
process
within
endosom
requir
process
newli
synthes
f
protein
also
success
viru
entri
niv
infect
carri
presenc
differ
inhibitor
infect
experi
minim
noncytotox
concentr
requir
maxim
cleavag
inhibit
determin
use
drug
inhibitor
ad
vero
cell
h
prior
infect
present
niv
infect
infecti
niv
bound
enter
cell
min
incub
result
effici
infect
shown
nonbound
virus
inhibitor
remov
h
infect
cell
cultur
serumfre
medium
h
post
infect
pi
supernat
taken
viru
titrat
determin
amount
infect
cell
visual
syncytium
format
cell
immunostain
use
polyclon
antiniv
serum
shown
fig
niv
infect
untreat
cell
control
induc
extens
celltocel
fusion
indic
format
larg
multinucl
syncytia
interestingli
neither
addit
endocytosi
inhibitor
sucros
mm
mcd
chlorpromazin
treatment
mm
nh
cl
addit
cathepsin
b
l
ctslspecif
inhibitor
catliii
effect
niv
infect
amount
size
syncytia
similar
control
infect
also
viru
titer
cell
supernat
substanti
differ
tabl
inhibitor
treatment
entri
control
vero
cell
infect
fowl
plagu
viru
fpv
condit
well
establish
entri
fusion
influenza
virus
absolut
depend
intern
acid
ph
within
endosom
marsh
heleniu
find
fpv
infect
drastic
reduc
either
endocytosi
sucros
acidif
endosom
mm
nh
cl
prevent
clearli
demonstr
viru
entri
effect
hinder
inhibitor
treatment
viru
adsorpt
fig
analyz
inhibitor
effect
ad
viru
entri
vero
cell
infect
niv
h
remov
nonbound
virus
cell
incub
serumfre
medium
contain
differ
inhibitor
sinc
mcd
highli
toxic
could
use
longer
incub
period
therefor
test
h
pi
outcom
infect
monitor
immunostain
infect
cell
titrat
infecti
viru
supernat
shown
fig
inhibitor
disrupt
endocyt
uptak
well
inhibitor
prevent
cathepsinmedi
proteolyt
process
drastic
reduc
syncytium
format
releas
infecti
virion
supernat
also
significantli
decreas
tabl
inhibitor
treatment
post
entri
determin
number
initi
infect
cell
sampl
nivposit
singl
cell
syncytia
origin
one
initi
infect
cell
ten
randomli
chosen
microscop
field
count
averag
mocktreat
cell
found
averag
syncytia
per
microscop
field
magnif
inhibitortr
cell
mean
number
singl
nivposit
cell
rang
thu
number
cell
initi
infect
niv
similar
infect
indic
inhibitor
treatment
interfer
viru
entri
initi
infect
sole
prevent
viru
spread
via
celltocel
fusion
releas
infecti
viru
particl
thu
endocytosi
acid
ph
cathepsinmedi
cleavag
import
initi
niv
infect
new
host
cell
requir
late
stage
infect
activ
newli
synthes
f
protein
find
impli
cellfre
niv
particl
contain
suffici
amount
cleav
f
protein
fulli
infecti
check
amount
cleav
f
protein
cellfre
virion
purifi
niv
cell
supernat
viru
prepar
separ
sd
gel
blot
nitrocellulos
either
probe
polyclon
antiniv
serum
recogn
predominantli
n
p
g
protein
incub
fspecif
antiserum
direct
niv
f
cytoplasm
tail
thu
specif
detect
f
f
western
blot
analysi
shown
fig
reveal
f
protein
viru
prepar
cleav
clearli
confirm
f
cleavag
occur
incorpor
bud
virion
initi
stage
infect
envelop
virion
involv
attach
cell
surfac
receptor
follow
fusion
cellular
membran
releas
viral
nucleocapsid
cytoplasm
receptor
bind
low
ph
known
two
main
trigger
mechan
respons
conform
chang
viral
glycoprotein
lead
viruscel
fusion
phindepend
virus
paramyxovirus
structur
chang
fusion
protein
occur
interact
viral
receptor
lamb
et
al
phdepend
virus
toga
rhabdo
alpha
flaviand
orthomyxovirus
low
ph
trigger
conform
chang
fusion
protein
intern
endosom
jardetzki
lamb
kielian
rey
endocyt
uptak
mani
differ
pathway
use
virus
includ
macropinocytosi
phagocytosi
clathrinand
caveolaemedi
pathway
lesswel
defin
rout
call
nonclathrin
noncaveolaedepend
pathway
marsh
heleniu
addit
phand
endocytosisdepend
entri
strategi
recent
propos
ebola
viru
sar
coronaviru
sarscov
virus
enter
new
host
cell
via
endocytosi
follow
aciddepend
digest
cathepsin
accomplish
fusion
compet
viral
glycoprotein
chandran
et
al
kaletski
et
al
schornberg
et
al
simmon
et
al
least
coronavirus
known
member
viru
famili
use
distinct
pathway
fusion
protein
activ
viru
entri
wherea
sarscov
mous
hepat
viru
mhv
requir
uptak
endocytosi
subsequ
proteolysi
cathepsin
qiu
et
al
simmon
et
al
infecti
bronchiti
viru
need
acidif
step
chu
et
al
strain
human
cov
enter
cell
phindepend
fusion
plasma
membran
huang
et
al
qiu
et
al
find
niv
f
protein
must
activ
endosom
proteas
rais
possibl
niv
similar
sarscov
ebola
viru
contrast
paramyxovirus
depend
phand
ctsldepend
mechan
entri
idea
niv
use
pathway
direct
fusion
plasma
membran
also
encourag
recent
report
newcastl
diseas
viru
ndv
prototyp
member
paramyxoviru
famili
enter
cell
via
caveolaemedi
endocytosi
cantin
et
al
sinc
raftand
thu
caveolaeassoci
membran
protein
gauthier
robbin
furthermor
constitut
intern
cell
surfac
niv
might
enter
caveosom
via
receptormedi
endocytosi
support
hypothesi
found
vlp
uptak
affect
mcd
inhibitor
caveolaemedi
endocytosi
howev
mcd
sucros
chlorpromazin
treatment
viru
entri
slight
neg
effect
product
viru
infect
indic
none
endocyt
pathway
requir
earli
viru
replic
step
consequ
aciddepend
endosom
f
cleavag
ctsl
prerequisit
success
niv
entri
agreement
addit
nh
cl
cathepsin
inhibitor
earli
viru
replic
step
significantli
reduc
infect
even
result
rule
endosom
entri
pathway
altern
rout
viru
entri
clearli
show
post
entri
f
process
endosom
requir
infect
niv
similar
paramyxovirus
furinactivat
f
protein
measl
mump
viru
niv
f
cleavag
occur
viru
assembl
incorpor
bud
viru
particl
contrast
paramyxoviru
f
protein
activ
furin
surfaceexpress
niv
f
protein
uncleav
even
newli
synthes
niv
f
protein
cleav
within
h
vero
cell
compar
fig
less
protein
found
cell
surfac
proteolyt
process
fusion
activ
moll
et
al
like
due
ineffici
recycl
plasma
membran
clathrinmedi
uptak
ctsl
cleavag
endocytos
f
protein
sinc
paramyxoviru
assembl
mainli
direct
interact
matrix
protein
cytoplasm
transmembran
portion
viral
glycoprotein
peebl
proteolyt
process
f
ectodomain
influenc
incorpor
bud
particl
thu
content
cleav
f
protein
cellfre
viru
particl
directli
depend
amount
activ
protein
present
cellular
compart
assembl
process
taken
place
fact
despit
low
amount
cleav
f
protein
plasma
membran
fulli
infecti
niv
particl
contain
cleav
fusionact
f
protein
releas
infect
cell
might
indic
nivassembl
occur
cell
surfac
endosom
membran
fit
concept
second
niv
envelop
glycoprotein
g
protein
also
intern
cell
surfac
vogt
et
al
recent
find
niv
protein
contain
late
domain
motif
yxxl
type
known
interact
compon
clathrinassoci
adaptor
complex
function
format
multivesicular
bodi
special
endocyt
compart
ciancanelli
basler
chen
et
al
iri
et
al
puffer
et
al
support
idea
endosom
compart
involv
proteolyt
activ
f
protein
might
also
site
viral
compon
recruit
viru
assembl
togeth
result
clearli
demonstr
despit
intern
niv
receptor
niv
particl
endocytosi
post
entri
cleavag
mechan
definit
requir
niv
entri
process
even
though
proteolyt
activ
niv
f
protein
clearli
differ
paramyxovirus
respect
proteas
usag
ctsl
subcellular
local
cleavag
take
place
endosom
niv
particl
releas
infect
cell
contain
suffici
amount
cleav
fusioncompet
f
protein
initi
infect
new
host
cell
phindepend
fusion
plasma
membran
vero
hela
cell
maintain
dulbecco
modifi
minim
essenti
medium
dmem
gibco
supplement
fetal
calf
serum
fc
unitsml
penicillin
mgml
streptomycin
pae
porcin
aortic
endotheli
cell
grown
glutamax
gibco
supplement
fc
penicillin
streptomycin
mdck
madindarbi
canin
kidney
cell
propag
mem
contain
fc
antibiot
niv
strain
use
studi
isol
human
brain
kindli
provid
j
cardosa
propag
describ
previous
moll
et
al
niv
infect
studi
vero
cell
infect
niv
multipl
infect
moi
incub
h
viru
remov
extens
wash
cell
cultur
dmem
without
fc
h
prepar
purifi
viru
virusuptak
experi
western
blot
analysi
vero
cell
infect
niv
moi
h
post
infect
supernat
centrifug
rpm
min
remov
cell
debri
pellet
sucros
cushion
rpm
h
rotor
beckman
resuspend
viru
pellet
buffer
contain
mm
tri
ph
mm
nacl
mm
edta
tne
centrifug
step
rpm
min
rotor
beckman
concentr
partial
purifi
niv
suspend
phosphat
buffer
salin
pb
bovin
serum
albumin
bsa
experi
live
niv
perform
condit
cdna
fragment
span
g
f
gene
niv
genom
genbank
access
number
clone
vector
describ
earlier
moll
et
al
allow
detect
protein
commerci
avail
antibodi
tag
version
protein
establish
insert
amino
acid
ypydvpdya
human
influenza
hemagglutinin
ha
known
hatag
cterminu
express
level
biolog
activ
hatag
protein
unchang
compar
parent
f
g
protein
transient
transfect
human
gene
kindli
provid
pfaff
h
augustin
subclon
noti
saci
restrict
site
pcagg
express
plasmid
vero
mdck
hela
cell
transfect
use
cation
lipid
transfect
reagent
lipofectamin
invitrogen
follow
instruct
supplier
stabli
pae
cell
gener
describ
fuller
et
al
kindli
provid
h
augustin
vlp
gener
describ
wahljensen
et
al
briefli
cell
transfect
plasmid
encod
niv
g
tag
use
calcium
phosphat
transfect
procedur
profect
mammalian
transfect
system
promega
h
post
transfect
supernat
harvest
clarifi
cellular
debri
centrifug
rpm
min
pellet
sucros
cushion
rpm
h
rotor
beckman
wash
pellet
suspend
pb
centrifug
rpm
min
final
vlpcontain
pellet
resuspend
tne
contain
bsa
store
vlp
prepar
control
electron
microscopi
western
blot
analysi
use
antihatag
antibodi
uptak
assay
cell
grown
cover
slip
subconflu
recombin
mous
solubl
receptor
fuse
fc
region
human
igg
r
system
ad
concentr
incub
h
allow
bind
endocytosi
occur
surfaceremain
visual
rhodamineconjug
antihuman
igg
antibodi
dilut
jackson
immunoresearch
min
fixat
permeabil
methanolaceton
intern
stain
fluorescein
isothiocyan
fitc
conjug
antihuman
igg
antibodi
dilut
dako
min
fluoresc
imag
record
use
zeiss
axiovert
microscop
endocytosi
inhibit
incub
sucros
serva
chlorpromazin
sigma
mm
mcd
sigma
acidif
endosom
block
addit
mm
nh
cl
sigma
cathepsinmedi
proteolysi
prevent
addit
either
sigma
catliii
calbiochem
sigma
chemic
drug
dissolv
water
dimethylsulfoxid
catliii
vero
cell
cultur
cover
slip
pretreat
dmem
contain
fc
supplement
sucros
chlorpromazin
mm
min
cell
incub
h
purifi
vlp
combin
monoclon
antibodi
direct
hatag
dilut
sigma
presenc
absenc
inhibitor
control
untreat
cell
incub
h
vlp
antibodi
direct
hatag
surfacebound
vlp
stain
incub
fitcconjug
antimous
igg
antibodi
jackson
immunoresearch
min
fixat
permeabil
methanolaceton
intracellular
vlp
detect
rhodamineconjug
secondari
antibodi
jackson
immunoresearch
min
visual
cell
nuclei
dapi
ad
secondari
antibodi
repres
imag
merg
dapi
fitc
rhodamin
channel
record
zeiss
axiovert
microscop
vero
cell
grown
chamber
slide
permanox
slide
nunc
labtek
incub
purifi
niv
particl
h
addit
polyclon
antiniv
serum
infect
guinea
pig
dilut
min
ice
cell
wash
sever
time
remov
unbound
viru
incub
antiniv
guinea
pig
serum
either
shift
kept
min
subsequ
surfacebound
virus
stain
incub
fitcconjug
antiguinea
pig
antibodi
dilut
jackson
immunoresearch
h
fixat
permeabil
methanolaceton
intracellular
virusantibodi
complex
visual
rhodamineconjug
secondari
antibodi
dilut
jackson
immunoresearch
h
cell
nuclei
stain
describ
final
cell
incub
paraformaldehyd
h
imag
record
perform
describ
studi
effect
differ
drug
inhibit
endocytosi
acidif
cathepsin
niv
f
protein
cleavag
vero
cell
transfect
plasmid
dna
encod
niv
f
gene
h
post
transfect
cell
incub
min
medium
lack
cystein
methionin
preincub
follow
incub
medium
contain
cystein
methionin
promix
ge
healthcar
final
concentr
min
puls
subsequ
label
medium
replac
serumfre
medium
h
chase
inhibitor
present
preincub
puls
chase
period
metabol
label
cell
lyse
radioimmunoprecipit
assay
ripa
buffer
triton
sodium
deoxychol
sd
nacl
mm
edta
mm
iodoacetamid
mm
pmsf
unitsml
aprotinin
mm
trishcl
ph
follow
centrifug
rpm
min
niv
f
protein
immunoprecipit
cell
lysat
polyclon
antiniv
serum
final
dilut
addit
suspens
protein
asepharos
sigma
immun
complex
wash
three
time
ripa
buffer
suspend
reduc
sampl
buffer
separ
polyacrylamid
gel
dri
gel
expos
autoradiographi
film
ge
healthcar
investig
effect
inhibitor
differ
stage
infect
cell
left
untreat
control
treat
differ
chemic
drug
inhibit
endocytosi
acidif
cathepsin
cleavag
inhibitor
either
ad
h
infect
h
viru
adsorpt
entri
inhibitor
treatment
entri
ad
h
viru
entri
inhibitor
treatment
entri
niv
infect
perform
describ
amount
infect
cell
syncytium
format
determin
indirect
immunofluoresc
fixat
paraformaldehyd
h
permeabil
methanolaceton
cell
incub
polyclon
guinea
pig
antiniv
serum
dilut
h
primari
antibodi
detect
rhodamineconjug
secondari
antibodi
dilut
imag
record
use
zeiss
axiophot
microscop
viru
titer
supernat
determin
tissu
cultur
infect
dose
tcid
method
vero
cell
reed
muench
control
effect
inhibitor
viru
entri
vero
cell
left
untreat
treat
inhibitor
h
inocul
influenza
viru
fpv
moi
absenc
presenc
inhibitor
h
wash
inactiv
residu
viru
attach
cell
surfac
dmem
adjust
ph
min
cell
incub
h
later
cell
fix
methanolaceton
fpvinfect
cell
stain
fpvspecif
monoclon
antibodi
kindli
provid
w
garten
dilut
h
primari
antibodi
detect
incub
rhodamineconjug
secondari
antibodi
dilut
jackson
immunoresearch
cell
nuclei
visual
describ
repres
imag
record
use
zeiss
axiovert
microscop
concentr
partial
purifi
niv
inactiv
disrupt
reduc
sampl
buffer
contain
sd
subsequ
heat
min
pellet
supernat
mock
infect
vero
cell
serv
control
separ
sd
gel
protein
transfer
nitrocellulos
nonspecif
bind
site
block
nonfat
dri
milk
pb
blot
either
incub
polyclon
antiniv
guinea
pig
serum
dilut
follow
incub
horseradish
peroxidaseconjug
rabbit
antiguinea
pig
immunoglobulin
dilut
dako
probe
fspecif
antibodi
direct
amino
acid
niv
f
cytoplasm
domain
dilut
pb
immunoglob
gmbh
follow
incub
biotinlabel
antirabbit
immunoglobulin
dilut
amersham
horseradish
peroxidaseconjug
streptavidin
dilut
amersham
protein
band
visual
enhanc
chemiluminesc
system
pico
pierc
exposur
autoradiographi
film
ge
healthcar
